Citius Pharmaceuticals Stock Performance
| CTXR Stock | USD 3.32 0.28 7.78% |
The firm shows a Beta (market volatility) of 1.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Citius Pharmaceuticals will likely underperform. At this point, Citius Pharmaceuticals has a negative expected return of -1.78%. Please make sure to confirm Citius Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Citius Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Citius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (7.78) | Five Day Return (27.83) | Year To Date Return (83.58) | Ten Year Return (99.28) | All Time Return (99.11) |
Last Split Factor 1:15 | Dividend Date 2017-06-09 | Last Split Date 2017-06-09 |
1 | Disposition of 2234700 shares by Leonard Mazur of Citius Pharmaceuticals at 0.77 subject to Rule 16b-3 | 09/25/2024 |
2 | Armistice Capital LLC Acquires Shares of 10,156,000 Citius Pharmaceuticals, Inc. - MarketBeat | 09/26/2024 |
3 | Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 | 10/25/2024 |
4 | Acquisition by Holuka Eugene Myron of 25000 shares of Citius Pharmaceuticals at 1.69 subject to Rule 16b-3 | 10/29/2024 |
5 | Acquisition by Holuka Eugene Myron of 125000 shares of Citius Pharmaceuticals at 0.38 subject to Rule 16b-3 | 11/07/2024 |
6 | Acquisition by Myron Holubiak of 175000 shares of Citius Pharmaceuticals at 0.67 subject to Rule 16b-3 | 11/08/2024 |
7 | Citius Pharmaceuticals stock hits 52-week low at 0.31 - Investing.com | 11/14/2024 |
8 | Acquisition by Myron Holubiak of 350000 shares of Citius Pharmaceuticals at 0.38 subject to Rule 16b-3 | 11/15/2024 |
9 | Citius Pharmaceuticals Announces Closing of 3 Million Registered Direct Offering | 11/18/2024 |
10 | Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - PR Newswire | 11/22/2024 |
11 | Citius Pharmaceuticals Shares Gap Down Whats Next | 11/27/2024 |
| Begin Period Cash Flow | 41.7 M |
Citius |
Citius Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,368 in Citius Pharmaceuticals on September 2, 2024 and sell it today you would lose (1,036) from holding Citius Pharmaceuticals or give up 75.73% of portfolio value over 90 days. Citius Pharmaceuticals is currently does not generate positive expected returns and assumes 8.6104% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than Citius, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Citius Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Citius Pharmaceuticals, and traders can use it to determine the average amount a Citius Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2067
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTXR |
Estimated Market Risk
| 8.61 actual daily | 76 76% of assets are less volatile |
Expected Return
| -1.78 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Citius Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Citius Pharmaceuticals by adding Citius Pharmaceuticals to a well-diversified portfolio.
Citius Pharmaceuticals Fundamentals Growth
Citius Stock prices reflect investors' perceptions of the future prospects and financial health of Citius Pharmaceuticals, and Citius Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Citius Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 8.06 M | ||||
| Shares Outstanding | 180.72 M | ||||
| Price To Earning | (1.34) X | ||||
| Price To Book | 0.30 X | ||||
| EBITDA | (36.73 M) | ||||
| Net Income | (32.54 M) | ||||
| Cash And Equivalents | 48.04 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 481.25 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (29.06 M) | ||||
| Earnings Per Share | (0.24) X | ||||
| Market Capitalization | 87.15 M | ||||
| Total Asset | 103.61 M | ||||
| Retained Earnings | (162.23 M) | ||||
| Working Capital | 28.59 M | ||||
| Current Asset | 893 K | ||||
| Current Liabilities | 5.18 M | ||||
About Citius Pharmaceuticals Performance
Assessing Citius Pharmaceuticals' fundamental ratios provides investors with valuable insights into Citius Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Citius Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.84) | (0.88) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.28) | (0.30) | |
| Return On Equity | (0.41) | (0.39) |
Things to note about Citius Pharmaceuticals performance evaluation
Checking the ongoing alerts about Citius Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Citius Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Citius Pharmaceuticals generated a negative expected return over the last 90 days | |
| Citius Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (32.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Pharmaceuticals currently holds about 48.04 M in cash with (29.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Citius Pharmaceuticals Shares Gap Down Whats Next |
- Analyzing Citius Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Citius Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Citius Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Citius Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Citius Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Citius Pharmaceuticals' stock. These opinions can provide insight into Citius Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.